237 related articles for article (PubMed ID: 33762352)
21. Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Plesca I; Tunger A; Müller L; Wehner R; Lai X; Grimm MO; Rutella S; Bachmann M; Schmitz M
Front Immunol; 2020; 11():364. PubMed ID: 32194568
[TBL] [Abstract][Full Text] [Related]
22. Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1-isoform of the Slamf6 receptor.
Keszei M; Detre C; Castro W; Magelky E; O'Keeffe M; Kis-Toth K; Tsokos GC; Wang N; Terhorst C
FASEB J; 2013 Aug; 27(8):3123-31. PubMed ID: 23629864
[TBL] [Abstract][Full Text] [Related]
23. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
24. Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy.
Zhang YX; Zhao YY; Shen J; Sun X; Liu Y; Liu H; Wang Y; Wang J
Nano Lett; 2019 May; 19(5):2774-2783. PubMed ID: 30943039
[TBL] [Abstract][Full Text] [Related]
25. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
[TBL] [Abstract][Full Text] [Related]
26. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
28. T Cells Regulate Peripheral Naive Mature B Cell Survival by Cell-Cell Contact Mediated through SLAMF6 and SAP.
Radomir L; Cohen S; Kramer MP; Bakos E; Lewinsky H; Barak A; Porat Z; Bucala R; Stepensky P; Becker-Herman S; Shachar I
J Immunol; 2017 Oct; 199(8):2745-2757. PubMed ID: 28904129
[TBL] [Abstract][Full Text] [Related]
29. ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes.
Yanguas A; Garasa S; Teijeira Á; Aubá C; Melero I; Rouzaut A
Front Immunol; 2018; 9():2084. PubMed ID: 30258446
[TBL] [Abstract][Full Text] [Related]
30. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
31. Slamf6 negatively regulates autoimmunity.
Wang N; Keszei M; Halibozek P; Yigit B; Engel P; Terhorst C
Clin Immunol; 2016 Dec; 173():19-26. PubMed ID: 27368806
[TBL] [Abstract][Full Text] [Related]
32. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z
Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427
[TBL] [Abstract][Full Text] [Related]
34. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.
Myers DR; Abram CL; Wildes D; Belwafa A; Welsh AMN; Schulze CJ; Choy TJ; Nguyen T; Omaque N; Hu Y; Singh M; Hansen R; Goldsmith MA; Quintana E; Smith JAM; Lowell CA
Front Immunol; 2020; 11():576310. PubMed ID: 33133093
[TBL] [Abstract][Full Text] [Related]
35. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice.
Tabbekh M; Franciszkiewicz K; Haouas H; Lécluse Y; Benihoud K; Raman C; Mami-Chouaib F
J Immunol; 2011 Jul; 187(1):102-9. PubMed ID: 21622855
[TBL] [Abstract][Full Text] [Related]
36. [A preliminary study on SLAMF6 expression in patients with severe aplastic anemia].
Zeng LJ; Liu CY; Ding SX; Zhang T; Shao ZH; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2018 Nov; 39(11):927-931. PubMed ID: 30486590
[No Abstract] [Full Text] [Related]
37. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
38. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
39. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
40. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
